Literature DB >> 2457110

The management of symptoms in advanced cancer: experience in a hospital-based continuing care unit.

P J Hoskin1, G W Hanks.   

Abstract

The treatment received by 158 patients with advanced cancer admitted over one year to the Continuing Care Unit at the Royal Marsden Hospital has been reviewed. The unit is an integral part of the hospital and this is reflected in the fact that 46 patients (29%) received radiotherapy, hormone therapy, chemotherapy or surgery in addition to symptomatic treatment for palliation of troublesome symptoms. One hundred and thirty-one patients received oral morphine in doses ranging from 2.5 mg 4-hourly to 700 mg 4-hourly. Patients with renal or hepatic impairment required lower doses of morphine and there was a highly significant inverse relationship between morphine dose and age. Eighty-five patients (54%) received parenteral diamorphine at some time due to their inability to take oral morphine. One hundred and twenty-three patients (78%) received a co-analgesic drug and anti-emetics were required by 78 patients (49% overall; 56% of those receiving morphine). Transcutaneous electrical nerve stimulation, acupuncture and relaxation were employed in selected patients, and graduated compression sleeves were used to treat lymphoedema. These data highlight the wide range of therapeutic options available to control the symptoms of advanced cancer and also indicate that tumoricidal treatments used in conjunction with symptomatic treatments may have a significant part to play.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2457110      PMCID: PMC1291628          DOI: 10.1177/014107688808100615

Source DB:  PubMed          Journal:  J R Soc Med        ISSN: 0141-0768            Impact factor:   5.344


  8 in total

1.  Pain, the physiological antagonist of opioid analgesics.

Authors:  G W Hanks; R G Twycross
Journal:  Lancet       Date:  1984-06-30       Impact factor: 79.321

2.  Antiemetics for terminal cancer patients.

Authors:  G W Hanks
Journal:  Lancet       Date:  1982-06-19       Impact factor: 79.321

3.  Antiemetic drug combinations in advanced cancer.

Authors:  T D Walsh
Journal:  Lancet       Date:  1982-05-01       Impact factor: 79.321

4.  Age-related morphine kinetics.

Authors:  J A Owen; D S Sitar; L Berger; L Brownell; P C Duke; P A Mitenko
Journal:  Clin Pharmacol Ther       Date:  1983-09       Impact factor: 6.875

5.  Metabolism of narcotics.

Authors:  C F Regnard; R G Twycross
Journal:  Br Med J (Clin Res Ed)       Date:  1984-03-17

6.  Age and morphine analgesia in cancer patients with postoperative pain.

Authors:  R F Kaiko
Journal:  Clin Pharmacol Ther       Date:  1980-12       Impact factor: 6.875

Review 7.  Control of pain.

Authors:  R G Twycross
Journal:  J R Coll Physicians Lond       Date:  1984-01

8.  Pain control in advanced cancer: pharmacological methods.

Authors:  G W Hanks; P J Hoskin
Journal:  J R Coll Physicians Lond       Date:  1986-10
  8 in total
  3 in total

1.  Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain: relationship to renal function and route of administration.

Authors:  G M Peterson; C T Randall; J Paterson
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Terminal cancer care and patients' preference for place of death: a prospective study.

Authors:  J Townsend; A O Frank; D Fermont; S Dyer; O Karran; A Walgrove; M Piper
Journal:  BMJ       Date:  1990-09-01

3.  Morphine: pharmacokinetics and clinical practice.

Authors:  P J Hoskin; G W Hanks
Journal:  Br J Cancer       Date:  1990-11       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.